Navigation Links
Oclaro Announces Second Quarter Fiscal Year 2013 Financial Results
Date:1/31/2013

SAN JOSE, Calif., Jan. 31, 2013 /PRNewswire/ -- Oclaro, Inc. (NASDAQ: OCLR), a provider of optical components, modules and subsystems, today announced the financial results for its second quarter of fiscal year 2013, which ended December 29, 2012.

"Our financial results for the second quarter of fiscal 2013 demonstrate the progress we are making after the merger," said Alain Couder, chairman and CEO. "Our revenues were at the top-end of guidance and we have successfully executed to the planned synergies on schedule. We also took action to strengthen our balance sheet.  Looking ahead, market and economic conditions remain uncertain in a typically softer March quarter. As a result, our efforts will remain focused on reducing operating expenses and improving margin, as well as capitalizing on our new product introductions and strong customer relationships to maximize revenues."

Results for the Second Quarter of Fiscal 2013:Oclaro closed its merger with Opnext, Inc. on July 23, 2012. The financial results for the second quarter of fiscal 2013 include a full quarter of operating results of Opnext. The financial results for the first quarter of fiscal 2013 include approximately ten weeks of operating results of Opnext since the closing of the merger. Results for the second quarter of fiscal 2012 were pre-merger Oclaro and do not include the operating results of Opnext.

  • Revenues were $159.5 million for the second quarter of fiscal 2013, compared with revenues of $148.8 million in the first quarter of fiscal 2013. Pro forma combined revenues for the first quarter of fiscal 2013, including Opnext for the full quarter, were $160.2 million.
  • GAAP gross margin was 13% for the second quarter of fiscal 2013, compared with a GAAP gross margin of 12% in the first quarter of fiscal 2013.
  • Non-GAAP gross margin was 15% for the second quarter of fisca
    '/>"/>

  • SOURCE Oclaro, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12

    Related medicine technology :

    1. Oclaro Announces Fourth Quarter and Fiscal Year 2012 Financial Results
    2. KaloBios Pharmaceuticals Announces Pricing of Initial Public Offering
    3. CryoLife Announces Release Date and Teleconference Call Details for 2012 Fourth Quarter and Year End Financial Results
    4. Blue Belt Technologies Announces First U.S. Sale of NavioPFS Surgical System
    5. IDEV Announces Results from Revascularization with Supera on Real World Patients (RESTORE) Study, Demonstrating Positive Clinical Outcomes in Significantly Diseased Patients with Long Lesions
    6. Vanda Announces Phase IIb/III Clinical Study In Major Depressive Disorder Did Not Meet The Primary Endpoint
    7. Targovax AS Announces First Patient Included in Phase I/II Clinical Study With the Therapeutic Cancer Vaccine TG01 in Operable Pancreatic Cancer
    8. Kemwell Announces Successful Pre-NDA US FDA Inspection
    9. Cell Therapeutics Announces Data Safety and Monitoring Board Recommendation to Continue the GOG-0212 Phase 3 Clinical Trial of OPAXIOTM as Maintenance Therapy in Ovarian Cancer
    10. Keryx Biopharmaceuticals Announces Pricing of Public Offering of Common Stock
    11. Vanish Announces Tattoo Removal Giveaway for Valentines Day
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/30/2014)... Biomedical Inc. ( www.synapsebiomedical.com ) announced today it ... of its NeuRx DPS® System for ALS patients.  ... enrollment requirement was implanted over a month and ... which is the only medical device approved by ... humanitarian device that obtained approval at the end ...
    (Date:9/30/2014)... EXECUTIVE SUMMARY The present report ... - Increasing Demand from Ageing Population to Drive ... past, present and future outlook. The report discusses ... market with outlook to 2017. Statistics include functional ... sub-segments of the industry, ongoing trends and developments, ...
    (Date:9/30/2014)... DURHAM, N.C. , Sept. 30, 2014 /PRNewswire/ ... that Viztek LLC (Viztek), a leading provider of ... licensed HeartIT,s zero footprint patent portfolio. The licensed ... to provide access to diagnostic-quality medical images in ... part of the agreement, Viztek and its Subsidiaries ...
    Breaking Medicine Technology:Synapse Biomedical Announces the Early Completion of Enrollment in the FDA Post Approval Study for ALS Patients 2Synapse Biomedical Announces the Early Completion of Enrollment in the FDA Post Approval Study for ALS Patients 3North America Nutraceuticals Industry Outlook to 2017- Increasing Demand from Ageing Population to Drive Growth 2North America Nutraceuticals Industry Outlook to 2017- Increasing Demand from Ageing Population to Drive Growth 3
    (Date:9/30/2014)... at the University of Michigan have described a new ... fraction of the time needed for more traditional methods. ... novel antibody that is undergoing further investigation as a ... , In research published online in the ... researchers in the lab of Stephen Weiss at the ...
    (Date:9/30/2014)... Fla. (PRWEB) September 30, 2014 Lea ... is giving breast cancer patients a new, more practical ... , Women who undergo mastectomies, biopsies and lumpectomy surgeries ... promote healing. But after seeing her patients describe the ... compelled to create a new bra in her spare ...
    (Date:9/30/2014)... (PRWEB) September 30, 2014 Brig Hart, ... history, who broke over 500 Diamond-ranked professionals using his ... doing it again. The Life Support System for ... he has been perfecting using his experiences and successes ... month. Using the principles and methodology taught by Brig ...
    (Date:9/30/2014)... Farmington, NY (PRWEB) September 30, 2014 Timber ... design/build process for the Olsen family’s reclaimed Douglas fir ... will cover the home’s journey from architectural planning, to the ... Dee Olsen turned to New Energy Works, after following the ... to design and build their dream vacation home on land ...
    (Date:9/30/2014)... September 30, 2014 ... , From:        Hope For The ... abarnwell(at)hopeforthewarriors(dot)org , Event:        Got ... , Date:        Thursday, October 2, ... and Navy Club, 901 ...
    Breaking Medicine News(10 mins):Health News:New discovery approach accelerates identification of potential cancer treatments 2Health News:Surgeon Creates New Bra for Breast Cancer Patients, Post-Surgery 2Health News:Surgeon Creates New Bra for Breast Cancer Patients, Post-Surgery 3Health News:Brig Hart Announces the First Diamond Elite Representatives using his Life Support System 2Health News:Brig Hart Announces the First Diamond Elite Representatives using his Life Support System 3Health News:Reclaimed Timber Frame Home By New Energy Works Featured in Timber Home Living Magazine 2Health News:Reclaimed Timber Frame Home By New Energy Works Featured in Timber Home Living Magazine 3Health News:Hope For The Warriors' Got Heart, Give Hope Celebration Media Advisory 2
    ... , , ... US Oncology, Inc . today announced that US Oncology ... Phase III, Multi-center, Open-Label, Randomized Trial of Gemcitabine/Carboplatin (G/C), with or ... HER2-negative metastatic breast cancer. , , ...
    ... , , , , ... its online boutique, www.chemo-couture.com , featuring inspirational, handcrafted ... and loved ones. , , Inspired ... disease, Jane Bebita and Julie Uhrig joined forces to create an ...
    ... , , SEOUL, South Korea, July ... 039350) is pleased to announce that its wholly owned subsidiary, ... for the commercial, institutional, and consumer markets, has successfully turned the ... the world) green! Royal Laundry of South San Francisco ...
    ... , , , ... Resources, one of the world,s leading research and advisory firms focusing ... market in Brazil will grow from $200 million in 2008 to ... the tumor necrosis factor-alpha (TNF-alpha) inhibitors Abbott,s Humira and Schering-Plough,s Remicade ...
    ... , , BRIDGEWATER, N.J., ... that it is possible to recruit large numbers of women, ... The study, known as GRACE, is the largest study to ... and race differences in response to an HIV-1 therapy -- ...
    ... , WHITE PLAINS, N.Y. and CAMBRIDGE, Mass., July ... FORMA Therapeutics today announced a partnership to accelerate LLS,s pipeline of ... , The collaboration will begin with a selection of ... to have the most promise of advancing into clinical trials in ...
    Cached Medicine News:Health News:US Oncology Research Network Participates in Phase III Follow-up Study to BiPar's Investigational Cancer Drug BSI-201 2Health News:US Oncology Research Network Participates in Phase III Follow-up Study to BiPar's Investigational Cancer Drug BSI-201 3Health News:US Oncology Research Network Participates in Phase III Follow-up Study to BiPar's Investigational Cancer Drug BSI-201 4Health News:HepaHope Korea Subsidiary VASKA Introduces Green Chemicals to U.S. Commercial Laundry Industry 2Health News:Brazil's Rheumatoid Arthritis Drug Market Will Grow $115 Million by 2013 2Health News:New HIV Study Shows That Large Numbers of Women and People of Color Can Be Successfully Enrolled In U.S. HIV Clinical Studies 2Health News:New HIV Study Shows That Large Numbers of Women and People of Color Can Be Successfully Enrolled In U.S. HIV Clinical Studies 3Health News:New HIV Study Shows That Large Numbers of Women and People of Color Can Be Successfully Enrolled In U.S. HIV Clinical Studies 4Health News:New HIV Study Shows That Large Numbers of Women and People of Color Can Be Successfully Enrolled In U.S. HIV Clinical Studies 5Health News:New HIV Study Shows That Large Numbers of Women and People of Color Can Be Successfully Enrolled In U.S. HIV Clinical Studies 6Health News:New HIV Study Shows That Large Numbers of Women and People of Color Can Be Successfully Enrolled In U.S. HIV Clinical Studies 7Health News:New HIV Study Shows That Large Numbers of Women and People of Color Can Be Successfully Enrolled In U.S. HIV Clinical Studies 8Health News:The Leukemia & Lymphoma Society and FORMA Therapeutics Enter Collaboration to Bring New Therapies to Patients Faster 2Health News:The Leukemia & Lymphoma Society and FORMA Therapeutics Enter Collaboration to Bring New Therapies to Patients Faster 3
    ... The AngioJet Xpeedior+120 Rheolytic Thrombectomy catheter is ... performance. Powerful saline jets create a low ... a vacuum effect. Thrombus is drawn into ... the jets, and removed from the body.,AngioJet ...
    ... combined with a stimulation lead ... Temporary Pacemaker can be used ... pacing is indicated. The device ... as well as diagnostic purposes ...
    ... a unique left ventricular assist device that helps ... being used in a small group of patients ... of an FDA-approved Feasibility Study. The patient can ... power source for minutes or hours. The Kantrowitz ...
    ... new Bicycle Ergometer ... braking system which ... reliable service while ... The hyperbolic workload ...
    Medicine Products: